Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.42 |
| ▸ | PDK1 | Q15118 | 4/20 | 0.42 |
| ▸ | MTOR | P42345 | 3/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.42 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | GPR3 | P46089 | 1/20 | 0.40 |
| ▸ | PDE4A | P27815 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17692468 | 0.75 | CYP1A2 (0.60) | NOS1CYP1A2CYP2C19PDPK1MAOA | |
| SCHEMBL30295893 | 0.74 | NOS1 (0.59) | NOS1CYP1A2CYP2C19PDPK1MAOA | |
| SCHEMBL29470689 | 0.71 | CYP1A2 (0.56) | NOS1CYP1A2CYP2C19PDPK1MAOA | |
| SCHEMBL21802595 | 0.71 | CYP1A2 (1.00) | NOS1CYP1A2CYP2C19PDPK1MAOA | |
| SCHEMBL1100756 | 0.71 | CYP1A2 (0.56) | NOS1CYP1A2CYP2C19PDPK1MAOA | |
| SCHEMBL16178927 | 0.71 | CYP1A2 (0.56) | NOS1CYP1A2CYP2C19PDPK1MAOA | |
| SCHEMBL6845122 | 0.71 | CYP1A2 (0.56) | NOS1CYP1A2CYP2C19PIK3CAPDK1 | |
| Hydrochloric Acid SCHEMBL30262984 | 0.70 | CYP1A2 (0.54) | NOS1CYP1A2CYP2C19PDPK1PIK3CA | |
| SCHEMBL12286155 | 0.68 | CYP1A2 (0.52) | NOS1CYP1A2CYP2C19PIK3CAPDK1 | |
| SCHEMBL20676148 | 0.67 | NOS1 (0.50) | NOS1CYP1A2CYP2C19PIK3CAPDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1255797-B2 | METHOD FOR ROUGHENING COPPER SURFACES FOR BONDING TO SUBSTRATES | OMG ELECTRONIC CHEMICALS INC (US) | 2016-10-12 | — | — | EP | claimed |
| EP-1255797-B1 | METHOD FOR ROUGHENING COPPER SURFACES FOR BONDING TO SUBSTRATES | OMG ELECTRONIC CHEMICALS INC (US) | 2012-06-13 | — | — | EP | claimed |
| JP-4754752-B2 | — | — | 2011-08-24 | — | — | JP | claimed |
| EP-1255797-A4 | METHOD FOR ROUGHENING COPPER SURFACES FOR BONDING TO SUBSTRATES | ELECTROCHEMICALS INC (US) | 2009-01-14 | — | — | EP | claimed |
| JP-2003519286-A | — | — | 2003-06-17 | — | — | JP | claimed |
| EP-1255797-A1 | METHOD FOR ROUGHENING COPPER SURFACES FOR BONDING TO SUBSTRATES | ELECTROCHEMICALS INC. (US) | 2002-11-13 | — | — | EP | claimed |
| WO-2001049805-A1 | METHOD FOR ROUGHENING COPPER SURFACES FOR BONDING TO SUBSTRATES | ELECTROCHEMICALS INC. (US) | 2001-07-12 | — | — | WO | claimed |
| EP-2432776-B1 | METHYL SULFANYL PYRIMIDINES USEFUL AS ANTIINFLAMMATORIES, ANALGESICS, AND ANTIEPILEPTICS | UNIV LAVAL (CA) | 2019-09-11 | — | — | EP | disclosed |
| EP-2432776-B1 | METHYL SULFANYL PYRIMIDINES USEFUL AS ANTIINFLAMMATORIES, ANALGESICS, AND ANTIEPILEPTICS | UNIV LAVAL (CA) | 2019-09-11 | — | — | EP | disclosed |
| EP-1255797-B2 | METHOD FOR ROUGHENING COPPER SURFACES FOR BONDING TO SUBSTRATES | OMG ELECTRONIC CHEMICALS INC (US) | 2016-10-12 | — | — | EP | disclosed |
| US-9315521-B2 | Pyrimidines as novel therapeutic agents | UNIVERSITé LAVAL (CA) | 2016-04-19 | — | — | US | disclosed |
| US-9315521-B2 | Pyrimidines as novel therapeutic agents | UNIVERSITé LAVAL (CA) | 2016-04-19 | — | — | US | disclosed |
| US-20150225423-A1 | PYRIMIDINES AS NOVEL THERAPEUTIC AGENTS | UNIVERSITé LAVAL (CA) | 2015-08-13 | — | — | US | disclosed |
| US-6716281-B2 | ADHESION PROMOTER COMPREISING OXIDIZER, PH ADJUSTER, TOPOGRAPHY MODIFIER; AND COATING STABILIZER COMPRISING 2-MERCAPTOTHIAZOLINE OR 2-MERCAPTOIMIDAZOLINE DERIVATIVE | ELECTROCHEMICALS, INC. | 2004-04-06 | — | — | US | disclosed |
| US-20040048486-A1 | Method for roughening copper surfaces for bonding to substrates | BERNARDS ROGER (US) | 2004-03-11 | — | — | US | disclosed |
| US-20030213553-A1 | Composition and method for preparing chemically-resistant roughened copper surfaces for bonding to substrates | MACDERMID, INCORPORATED | 2003-11-20 | — | — | US | disclosed |
| CN-1451031-A | Method for roughening copper surfaces for bonding to substrates | ELECTROCHEMICALS INC (US) | 2003-10-22 | — | — | CN | disclosed |
| EP-1255797-A1 | METHOD FOR ROUGHENING COPPER SURFACES FOR BONDING TO SUBSTRATES | ELECTROCHEMICALS INC. (US) | 2002-11-13 | — | — | EP | disclosed |
| US-20020084441-A1 | Method for roughening copper surfaces for bonding to substrates | MACDERMID, INCORPORATED | 2002-07-04 | — | — | US | disclosed |
| WO-2001049805-A1 | METHOD FOR ROUGHENING COPPER SURFACES FOR BONDING TO SUBSTRATES | ELECTROCHEMICALS INC. (US) | 2001-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225423-A1 | PYRIMIDINES AS NOVEL THERAPEUTIC AGENTS | TYMS, P2RX2, TYMP | NOS1 3128/4885CYP1A2 55/4885CYP2C19 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.